Aldoss et al. demonstrated that TP53 mutation was not detrimental in patients with t-MDS who underwent allo-HSCT and they had similar outcomes compared to the transplanted patients with de novo MDS with TP53 mutations. Here, TP53 is linked to myelodysplastic syndrome.